Biohazard levels and biosafety protection for n Mycobacterium tuberculosis strains with differen

来源 :生物安全与健康(英文) | 被引量 : 0次 | 上传用户:zhaojiagu
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Tuberculosis (TB) is a chronic infectious respiratory disease caused by n Mycobacterium tuberculosis (MTB), which seriously endangers human health. TB is transmitted through the respiratory tract and poses great biosafety risks to laboratory technicians and staff, through direct or indirect contact with MTB. Therefore, the comprehensive application of standard laboratory operating procedures, safety equipment, contingency plans, and other laboratory biosafety measures not only ensures the safe handling of potentially infectious microorganisms by laboratory workers but also strives to prevent the accidental exposure of potentially harmful pathogens to larger communities. In this article, we intend to discuss topics as biosafety risk assessments suitable for handling the biohazard levels of MTB strains, and the development of corresponding biosafety protection measures necessary for the biosafety of MTB testing and related research that will be implemented at different levels of laboratory and epidemiological situation.n “,”Tuberculosis (TB) is a chronic infectious respiratory disease caused by n Mycobacterium tuberculosis (MTB), which seriously endangers human health. TB is transmitted through the respiratory tract and poses great biosafety risks to laboratory technicians and staff, through direct or indirect contact with MTB. Therefore, the comprehensive application of standard laboratory operating procedures, safety equipment, contingency plans, and other laboratory biosafety measures not only ensures the safe handling of potentially infectious microorganisms by laboratory workers but also strives to prevent the accidental exposure of potentially harmful pathogens to larger communities. In this article, we intend to discuss topics as biosafety risk assessments suitable for handling the biohazard levels of MTB strains, and the development of corresponding biosafety protection measures necessary for the biosafety of MTB testing and related research that will be implemented at different levels of laboratory and epidemiological situation.n
其他文献
Hepatic resection represents the first-line treatment for patients with resectable hepatocellular carcinoma (HCC).However,the 5-year recurrence rates of HCC aft
Background:A novel coronavirus(the SARS-CoV-2)has been identified in January 2020 as the causal pathogen for COVID-19,a pandemic started near the end of 2019.Th
目的 探讨罗布麻叶水提取物(WEAVL)对链脲佐菌素(STZ)致糖尿病模型小鼠的治疗作用.方法 随机将ICR小鼠分为对照组和WEAVL(2.34g/kg)组,每天ig给药1次,连续30d,检测空腹血糖和
目的 研究治咳川贝枇杷滴丸(CBPP)的祛痰、镇咳作用,以及对肺组织Muc5AC表达的影响,明确其药效特点,为中药临床定位提供实验依据.方法 采用雄性SPF级ICR小鼠,分别为对照(生理
目的优化乌拉草总黄酮脂质体凝胶剂的制备工艺,并进行质量评价。方法乙醇注入法制备乌拉草总黄酮(CMTF)脂质体,以包封率为指标,正交试验优化处方;以脂质体凝胶剂的外观、涂展性、均匀度、黏稠度等综合评分为指标,采用Box-Behnken响应面法优化CMTF脂质体凝胶的处方及制备工艺。通过观察性状、pH值、铺展性及可洗除性,以及离心试验、耐寒及耐热试验,考察CMTF脂质体凝胶稳定性;观察其对大鼠正常及破损皮肤的刺激性。结果CMTF脂质体的最佳制备工艺为:大豆磷脂与胆固醇的质量比为5∶3,大豆磷脂与CMTF的质量
Background:The lipostatic set-point theory,ascribing fat mass homeostasis to leptin mediated central feedback regulation targeting the body's fat storage,has ca
目的 探讨丹灯通脑胶囊联合丁苯酞治疗急性脑梗死的临床效果.方法 选取2018年8月-2020年7月南阳市中心医院收治的86例急性脑梗死患者,按照治疗方法将患者分成对照组(n=43)和
目的探讨麝香四黄颗粒联合注射用阿替普酶治疗痰热腑实型急性缺血性脑梗死患者的疗效。方法选取2019年7月—2020年12月潍坊市中医院急诊收入的80例痰热腑实型急性缺血性脑梗死患者,按照治疗方法将患者分为对照组和观察组,每组各40例。对照组予以注射用阿替普酶,其中所需总量的10%在1 min内静脉推注,剩余90%静脉泵入60 min;观察组在对照组的基础上冲服麝香四黄颗粒,1剂/d,分早晚2次服,疗程为14 d。观察两组患者的临床疗效和中医疗效,比较两组的美国国立卫生研究院脑梗死量表评分(NIHSS)、Ba
为促进新型冠状病毒肺炎(COVID-19)疫苗和治疗药物在欧盟的开发和应用,欧洲药品管理局(EMA)于2020年12月发布了“COVID-19疫苗说明书灵活性问答”,并于2021年3月又发布了“CO